Hemogenyx Pharmaceuticals PLC
LSE:HEMO

Watchlist Manager
Hemogenyx Pharmaceuticals PLC Logo
Hemogenyx Pharmaceuticals PLC
LSE:HEMO
Watchlist
Price: 795 GBX -2.81% Market Closed
Market Cap: £47.1m

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
£0
/
£0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
GBX0
/
£0

Peer Comparison

Country Company Market Cap Operating
Margin
UK
Hemogenyx Pharmaceuticals PLC
LSE:HEMO
48.4m GBP
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
393.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
172.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.4B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Hemogenyx Pharmaceuticals PLC
Glance View

Market Cap
47.1m GBX
Industry
Biotechnology

HemoGenyx Pharmaceuticals Plc operates as a biopharmaceutical company, which engages in the development of novel therapies to transform bone marrow and blood stem cell transplantation. The firm is engaged in the discovery, development, and commercialization of a suite of products to address the problems associated with the treatment of blood disorders, such as cancers and autoimmune diseases, with viral infections, and with bone marrow, or hematopoietic stem cell, transplants. The Company’s product candidates include CDX antibody, CAR-T cell therapy, Hu-PHEC stem cell therapy, Humanised mice, and CBR platform. Its CDX antibody product, is a bispecific antibody targeting a form of relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia (ALL), and myelodysplastic syndrome. CAR-T cell therapy is a chimeric antigen receptor T-cells that are engineered for use in immunotherapy. The Company’s human postnatal hemogenic endothelial cells (Hu-PHECs) are a type of cell therapy that generate cancer-free hematopoietic stem cells for use in transplants to treat blood disorders.

HEMO Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top